Pharmaceutical group ยท United States
Gilead Sciences
A group of 19 companies with 264 medicines in 10 countries.
Group structure
19 companies in 10 countries
Loading your pageโฆ
Loading your pageโฆ
Pharmaceutical group ยท United States
A group of 19 companies with 264 medicines in 10 countries.
19 companies in 10 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 264
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AMBISOME FOR INJECTION 50 mg/vial50 mg/vial ยท Injection, powder, for solution | Amphotericin b | Singapore | Authorised | 2002 |
| AMBISOME LIPOSOMAL 50 MG POLVO PARA DISPERSION PARA PERFUSION50 mg ยท Polvo para dispersiรณn para perfusiรณn | Amphotericin b | Spain | Marketed | 1996 |
| AmBisome liposomale amfotericine B 50 mg, poeder voor dispersie voor infusiePoeder voor dispersie voor infusie | Amphotericin b | Netherlands | Authorised | 1993 |
| AMBISOME LIPOSOMIALEPolvere per soluzione per infusione endovenosa | Amphotericin b | Italy | Authorised | |
| ATRIPLA600MG; 200MG; 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท Tablet | Efavirenz, Emtricitabine, Tenofovir disoproxil | United States | Not marketed | 2006 |
| BIKTARVYCompressa rivestita con film | Emtricitabine, Bictegravir, Tenofovir alafenamide | Italy | Authorised | |
| BIKTARVY | Bictegravir, Entricitabina, Tenofovir alafenamide | Brazil | Authorised | 2019 |
| BIKTARVY50 mg + 200 mg + 25 mg ยท Tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | Canada | Marketed | 2018 |
| BIKTARVY30mg base; 120mg; 15mg base | 50mg base; 200mg; 25mg base ยท Tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | United States | Marketed | 2018 |
| Biktarvy | Bictegravir, Emtricitabine, Tenofovir alafenamide | EU (EMA) | Authorised | 2018 |
| Biktarvy 30 mg/120 mg/15 mg filmomhulde tablettenFilmomhulde tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | Netherlands | Authorised | 2022 |
| BIKTARVY 50 MG/200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA52,45 mg + 200 mg + 28,04 mg ยท Comprimido recubierto con pelรญcula | Bictegravir, Emtricitabine, Tenofovir alafenamide | Spain | Marketed | 2018 |
| BIKTARVY 50 MG/200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA50 mg + 200 mg + 25 mg ยท Comprimido recubierto con pelรญcula | Bictegravir, Emtricitabine, Tenofovir alafenamide | Spain | Marketed | 2025 |
| BIKTARVY 50 MG/200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA52,45 mg + 200 mg + 28,04 mg ยท Comprimido recubierto con pelรญcula | Bictegravir, Emtricitabine, Tenofovir alafenamide | Spain | Authorised | 2022 |
| Biktarvy 50 mg/200 mg/25 mg filmomhulde tablettenFilmomhulde tablet | Bictegravir, Emtricitabine, Tenofovir alafenamide | Netherlands | Authorised | 2018 |
| BIKTARVY FILM-COATED TABLETS 50MG/200MG/25MG50mg + 200mg + 25mg ยท Tablet, film coated | Bictegravir, Emtricitabine, Tenofovir alafenamide | Singapore | Authorised | 2019 |
| CAYSTONPolvere per inalazione | Aztreonam | Italy | Authorised | |
| CAYSTON75 mg / vial ยท Powder For Solution | Aztreonam | Canada | Marketed | 2009 |
| CAYSTON75mg/vial ยท For solution | Aztreonam | United States | Marketed | 2010 |
| Cayston | Aztreonam | EU (EMA) | Authorised | 2009 |
| Cayston 75 mg, poeder voor verneveloplossingPoeder voor verneveloplossing | Aztreonam | Netherlands | Authorised | 2009 |
| CAYSTON 75 mg POLVO Y DISOLVENTE PARA SOLUCION PARA INHALACION POR NEBULIZADOR75 mg ยท Polvo para soluciรณn para inhalaciรณn por nebulizador | Aztreonam | Spain | Marketed | 2010 |
| COMPLERA200 mg + 25 mg + 300 mg ยท Tablet | Emtricitabine, Rilpivirine, Tenofovir disoproxil | Canada | Marketed | 2011 |
| COMPLERA200mg; 25mg base; 300mg ยท Tablet | Emtricitabine, Rilpivirine, Tenofovir disoproxil | United States | Marketed | 2011 |
| Descovy | Entricitabina, Tenofovir alafenamide | Brazil | Authorised | 2019 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 45 | 42 | 3 | CompaniesAll medicines |
| Netherlands | 45 | 45 | 0 | CompaniesAll medicines |
| Canada | 36 | 28 | 8 | CompaniesAll medicines |
| United States | 36 | 36 | 0 | CompaniesAll medicines |
| European Union (EMA) | 27 | 23 | 4 | CompaniesAll medicines |
| Italy | 23 | 23 | 0 | CompaniesAll medicines |
| Brazil | 16 | 12 | 4 | CompaniesAll medicines |
| Romania | 15 | 0 | 15 | CompaniesAll medicines |
| Singapore | 12 | 12 | 0 | CompaniesAll medicines |
| Saudi Arabia | 9 | 9 | 0 | CompaniesAll medicines |
Also in the registers of France, Serbia, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.